Opioid treatment 2

Changes in the delivery of OAT during COVID-19 sparked renewed discussions on how to provide effective treatment for individuals seeking opioid therapy, along with a focus on improving evaluations of treatment outcomes and patient well-being across different approaches. This session examines opioid agonist treatment (OAT) and heroin-assisted treatment (HAT), exploring their implementation and effectiveness. Topics include the impact of policy changes and the pandemic on OAT use during pregnancy, international efforts to establish consensus on OAT outcome measures, and trends in OAT medication use in Australia. The session also covers the effects of dispensing practices on methadone-related deaths during the pandemic and health-related quality of life for HAT patients.